Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
143.7×+142×
Replimune Group logo
Replimune GroupREPL
3.6×+1.7×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
3.1×+1.7×
Erasca, Inc. logo
Erasca, Inc.ERAS
12.8×+11.8×
Arcus Biosciences logo
Arcus BiosciencesRCUS
5.2×+3.6×

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Calculated from OnKure Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s price / book?
OnKure Therapeutics, Inc. (OKUR) reported price / book of 1× in Q1 2026.
How has OnKure Therapeutics, Inc.'s price / book changed year-over-year?
OnKure Therapeutics, Inc.'s price / book decreased by 51.8% year-over-year, from 2× to 1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.